Ironwood beats on 2026 outlook thanks to higher sales from AbbVie-partnered Linzess
Source: SeekingAlpha
2026-01-02 07:29:00 ET
More on Ironwood Pharmaceuticals, AbbVie
- AbbVie: Solid Growth, Some Risks, And An Attractive Setup In 2026
- AbbVie: Unique Mix Of Growth And Value
- AbbVie Inc. (ABBV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
- Ironwood rises after settling Ferring lawsuit
- More pharmas expected to sign drug pricing deals with Trump on Friday - report
Read the full article on Seeking Alpha
For further details see:
Ironwood beats on 2026 outlook thanks to higher sales from AbbVie-partnered Linzess
Ironwood Pharmaceuticals Inc.
NASDAQ: IRWD
IRWD Trading
-6.99% G/L:
$3.46 Last:
657,491 Volume:
$3.57 Open:
IRWD Latest News
IRWD Stock Data
$754,015,529
142,018,459
0.3%
66
N/A
Pharmaceuticals
Healthcare
US
Boston
